newsfilter
← Latest News
GlobeNewswire·

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results

On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and Report Topline Results by the Fourth Quarter of 2024 Projected Cash Runway into First Half of 2025